Image Credit: Adobe Stock Images/LASZLOThe FDA has approved Johnson & Johnson’s (J&J) Darzalex Faspro in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT). After consolidation therapy, patients received an investigational treatment regimen for maintenance that included Darzalex Faspro in combination with either lenalidomide or lenalidomide alone. "Today's approval embodies our commitment to setting new standards of care for patients newly diagnosed with multiple myeloma who are transplant eligible." DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible. Key Statistics About Multiple Myeloma.

Source: New York Times July 31, 2024 18:00 UTC